Medicinal Chemical Properties of Successful Central Nervous System Drugs

Overview

Journal NeuroRx

Specialty Neurology

Date 2006 Feb 21

PMID 16489364

Citations 404

Authors

Hassan Pajouhesh

George R Lenz

Affiliations

Soon will be listed here.

Abstract

Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the blood-brain barrier affinity and exhibit CNS activity. Factors relevant to the success of CNS drugs are reviewed. CNS drugs show values of molecular weight, lipophilicity, and hydrogen bond donor and acceptor that in general have a smaller range than general therapeutics. Pharmacokinetic properties can be manipulated by the medicinal chemist to a significant extent. The solubility, permeability, metabolic stability, protein binding, and human ether-ago-go-related gene inhibition of CNS compounds need to be optimized simultaneously with potency, selectivity, and other biological parameters. The balance between optimizing the physiochemical and pharmacokinetic properties to make the best compromises in properties is critical for designing new drugs likely to penetrate the blood brain barrier and affect relevant biological systems. This review is intended as a guide to designing CNS therapeutic agents with better drug-like properties.

Citing Articles

Pharmacokinetics of Non-Psychotropic Phytocannabinoids.

Lacerda M, Carona A, Castanheira S, Falcao A, Bicker J, Fortuna A Pharmaceutics. 2025; 17(2).

PMID: 40006604 PMC: 11858989. DOI: 10.3390/pharmaceutics17020236.

C-Labeling of a Flavanone Extracted from a South American Native Species for Evaluation of Its Interaction with GSK-3β.

Zeni M, Santi M, Arredondo F, Reyes L, Bentura M, Carvalho D Molecules. 2025; 30(4).

PMID: 40005183 PMC: 11857971. DOI: 10.3390/molecules30040874.

Protection against Amyloid-β Aggregation and Ferroptosis/Oxytosis Toxicity by Arylpyrazolones: Alzheimer's Disease Therapeutics.

Soares P, Rahaman M, Maher P, Silverman R ACS Med Chem Lett. 2025; 16(2):294-300.

PMID: 39967645 PMC: 11831554. DOI: 10.1021/acsmedchemlett.4c00530.

Discovery of novel AR antagonist via 3D-QSAR pharmacophore modeling: neuroprotective effects in 6-OHDA-induced SH-SY5Y cells and haloperidol-induced Parkinsonism in C57 bl/6 mice.

Singh A, Prakash A, Mishra J, Luthra P Mol Divers. 2025; .

PMID: 39899125 DOI: 10.1007/s11030-025-11120-x.

Comparative Analysis of p Predictions for Arsonic Acids Using Density Functional Theory-Based and Machine Learning Approaches.

Nedyalkova M, Heredia D, Barroso-Flores J, Lattuada M ACS Omega. 2025; 10(3):3128-3140.

PMID: 39895757 PMC: 11780423. DOI: 10.1021/acsomega.4c10413.

References

Ajay A, Walters W, Murcko M . Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?. J Med Chem. 1998; 41(18):3314-24. DOI: 10.1021/jm970666c. View

Vieth M, Siegel M, Higgs R, Watson I, Robertson D, Savin K . Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem. 2003; 47(1):224-32. DOI: 10.1021/jm030267j. View

Schneeberger E, LYNCH R . Structure, function, and regulation of cellular tight junctions. Am J Physiol. 1992; 262(6 Pt 1):L647-61. DOI: 10.1152/ajplung.1992.262.6.L647. View

Ertel S, Ertel E, Clozel J . T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc Drugs Ther. 1998; 11(6):723-39. DOI: 10.1023/a:1007706022381. View

Mahar Doan K, Humphreys J, Webster L, Wring S, Shampine L, Serabjit-Singh C . Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002; 303(3):1029-37. DOI: 10.1124/jpet.102.039255. View

Adenot M, Lahana R . Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates. J Chem Inf Comput Sci. 2004; 44(1):239-48. DOI: 10.1021/ci034205d. View

Leeson P, Davis A . Time-related differences in the physical property profiles of oral drugs. J Med Chem. 2004; 47(25):6338-48. DOI: 10.1021/jm049717d. View

Clark D . Prediction of intestinal absorption and blood-brain barrier penetration by computational methods. Comb Chem High Throughput Screen. 2001; 4(6):477-96. DOI: 10.2174/1386207013330850. View

Mouritsen O, Jorgensen K . A new look at lipid-membrane structure in relation to drug research. Pharm Res. 1998; 15(10):1507-19. DOI: 10.1023/a:1011986613392. View

10.

Jorgensen W . The many roles of computation in drug discovery. Science. 2004; 303(5665):1813-8. DOI: 10.1126/science.1096361. View

11.

Iyer M, Mishra R, Han Y, Hopfinger A . Predicting blood-brain barrier partitioning of organic molecules using membrane-interaction QSAR analysis. Pharm Res. 2002; 19(11):1611-21. DOI: 10.1023/a:1020792909928. View

12.

Bannon A, Decker M, Holladay M, Curzon P, Puttfarcken P, Bitner R . Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 1998; 279(5347):77-81. DOI: 10.1126/science.279.5347.77. View

13.

Palm K, Luthman K, Ros J, Grasjo J, Artursson P . Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther. 1999; 291(2):435-43. View

14.

Lipinski C . Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2014; 1(4):337-41. DOI: 10.1016/j.ddtec.2004.11.007. View

15.

Ekins S . Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov Today. 2004; 9(6):276-85. DOI: 10.1016/S1359-6446(03)03008-3. View

16.

Liljebris C, Larsen S, Ogg D, Palazuk B, Bleasdale J . Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity. J Med Chem. 2002; 45(9):1785-98. DOI: 10.1021/jm011100y. View

17.

Fichert T, Yazdanian M, Proudfoot J . A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett. 2003; 13(4):719-22. DOI: 10.1016/s0960-894x(02)01035-1. View

18.

Fischer H, Gottschlich R, Seelig A . Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol. 1998; 165(3):201-11. DOI: 10.1007/s002329900434. View

19.

Strausberg R, Schreiber S . From knowing to controlling: a path from genomics to drugs using small molecule probes. Science. 2003; 300(5617):294-5. DOI: 10.1126/science.1083395. View

20.

Feng M . Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab. 2002; 3(6):647-57. DOI: 10.2174/1389200023337063. View